Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
Femasys (NASDAQ: FEMY) announces the European Patent Office's intention to grant two EU Patent Applications (24170531.8 and 18751753.7) for its FemBloc permanent birth control technology. The patents, expiring in 2039 and 2038 respectively, cover essential components of FemBloc's fallopian tube occlusion system, which provides a non-surgical alternative to traditional sterilization.
The company plans to pursue additional patent applications to strengthen its portfolio, which includes other products like FemaSeed, FemVue, FemCath, and FemCerv. This patent expansion in Europe precedes commercial availability and supports Femasys' mission to provide accessible women's health technologies globally.
Femasys (NASDAQ: FEMY) annuncia l'intenzione dell'Ufficio europeo dei brevetti di concedere due domande di brevetto UE (24170531.8 e 18751753.7) per la sua tecnologia di controllo delle nascite permanente FemBloc. I brevetti, in scadenza rispettivamente nel 2039 e 2038, coprono componenti essenziali del sistema di occlusione delle tube di Falloppio di FemBloc, che offre un'alternativa non chirurgica alla sterilizzazione tradizionale.
La società prevede di presentare ulteriori domande di brevetto per rafforzare il proprio portafoglio, che include altri prodotti come FemaSeed, FemVue, FemCath e FemCerv. Questa espansione di brevetti in Europa precede la disponibilità commerciale e supporta la missione di Femasys di fornire tecnologie per la salute delle donne accessibili a livello globale.
Femasys (NASDAQ: FEMY) anuncia la intención de la Oficina Europea de Patentes de conceder dos solicitudes de patente de la UE (24170531.8 y 18751753.7) para su tecnología de control de la natalidad permanente FemBloc. Las patentes, que expiran en 2039 y 2038 respectivamente, cubren componentes esenciales del sistema de oclusión de trompas de FemBloc, que proporciona una alternativa no quirúrgica a la esterilización tradicional.
La empresa planea buscar solicitudes de patente adicionales para fortalecer su cartera, que incluye otros productos como FemaSeed, FemVue, FemCath y FemCerv. Esta expansión de patentes en Europa precede la disponibilidad comercial y apoya la misión de Femasys de ofrecer tecnologías de salud para mujeres accesibles en todo el mundo.
Femasys (NASDAQ: FEMY)는 유럽 특허청이 두 개의 EU 특허 출원(24170531.8 및 18751753.7)을 FemBloc 영구 출산 통제 기술에 대해 부여할 의향을 발표했습니다. 각각 2039년과 2038년에 만료되는 이 특허는 FemBloc의 나팔관 차단 시스템의 필수 구성 요소를 포함하고 있으며, 전통적인 불임 수술에 대한 비수술적 대안을 제공합니다.
회사는 FemaSeed, FemVue, FemCath 및 FemCerv와 같은 다른 제품을 포함하는 포트폴리오를 강화하기 위해 추가 특허 출원을 진행할 계획입니다. 이 유럽 내 특허 확대는 상업적 가용성에 앞서 이루어지며, 전 세계적으로 접근 가능한 여성 건강 기술을 제공하겠다는 Femasys의 사명을 지원합니다.
Femasys (NASDAQ: FEMY) annonce l'intention de l'Office européen des brevets de délivrer deux demandes de brevet de l'UE (24170531.8 et 18751753.7) pour sa technologie de contraception permanente FemBloc. Les brevets, expirant respectivement en 2039 et 2038, couvrent des éléments essentiels du système d'occlusion des trompes de FemBloc, qui offre une alternative non chirurgicale à la stérilisation traditionnelle.
L'entreprise prévoit de déposer d'autres demandes de brevet pour renforcer son portefeuille, qui comprend d'autres produits comme FemaSeed, FemVue, FemCath et FemCerv. Cette expansion des brevets en Europe précède la disponibilité commerciale et soutient la mission de Femasys de fournir des technologies de santé pour les femmes accessibles à l'échelle mondiale.
Femasys (NASDAQ: FEMY) gibt bekannt, dass das Europäische Patentamt die Absicht hat, zwei EU-Patentanmeldungen (24170531.8 und 18751753.7) für die permanente Geburtenkontrolle FemBloc Technologie zu gewähren. Die Patente, die jeweils 2039 und 2038 ablaufen, decken wesentliche Komponenten des Eileiter-Okklusionssystems von FemBloc ab, das eine nicht-chirurgische Alternative zur traditionellen Sterilisation bietet.
Das Unternehmen plant, weitere Patentanmeldungen zu verfolgen, um sein Portfolio zu stärken, das andere Produkte wie FemaSeed, FemVue, FemCath und FemCerv umfasst. Diese Patentexpansion in Europa geht der kommerziellen Verfügbarkeit voraus und unterstützt die Mission von Femasys, weltweit zugängliche Technologien für die Gesundheit von Frauen bereitzustellen.
- Secured two new European patents for FemBloc technology
- Patents provide protection until 2038/2039
- Expanding intellectual property coverage in European market ahead of commercialization
- Product not yet commercially available in Europe
Insights
The securing of two European patents for FemBloc represents a significant strategic milestone for Femasys, particularly given the comprehensive protection until 2038-2039. This IP fortification is especially valuable in the European market, where medical device patents face rigorous scrutiny and where healthcare systems highly value cost-effective, minimally invasive solutions.
The timing is particularly strategic as it precedes commercial availability, creating a strong barrier to entry for potential competitors in the European market. The women's healthcare market in Europe, valued at several billion dollars, has shown increasing demand for non-surgical alternatives to traditional sterilization procedures. FemBloc's patent protection for both essential components suggests a robust technological moat that could translate into significant market share once commercialized.
From an investor perspective, these patent grants are particularly meaningful for three reasons:
- They protect both core components of the FemBloc system, making it more difficult for competitors to develop similar solutions
- The extended protection period through 2038-2039 provides a substantial window for market development and revenue generation
- The pre-commercial timing of these patents positions Femasys advantageously for potential European partnerships or licensing agreements
These developments align with Femasys's broader strategy of building a comprehensive women's health portfolio, which includes FemaSeed, FemVue, FemCath and FemCerv. The company's commitment to pursuing additional patent applications suggests a proactive approach to IP protection that could further enhance their competitive position in the global women's healthcare market.
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception
ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the European Patent Office (“EPO”) issued notices of Intention to Grant for two EU Patent Applications, EPO Application Nos. 24170531.8 and 18751753.7, which will have anticipated expirations in 2039 and 2038, respectively. Femasys plans to pursue additional patent applications to further strengthen its existing portfolio protecting FemBloc® permanent birth control, along with its other products, including FemaSeed®, FemVue®, FemCath® and FemCerv®.
“The allowance of all requested claims for the two components of the non-surgical FemBloc permanent birth control marks a key milestone in extending protection for this revolutionary alternative to traditional surgical sterilization, which is costly, inconvenient, and carries significant risks,” stated Kathy Lee-Sepsick, Femasys’ CEO. “Expanding our patent protection and coverage in Europe ahead of commercial availability brings us one step closer to advancing Femasys' mission to deliver essential technologies to women globally.”
About FemBloc
FemBloc® is a revolutionary first-of-its-kind non-surgical permanent birth control, that involves a minimally invasive delivery system to introduce a specially designed blended polymer into the fallopian tubes, triggering a natural healing response that blocks the tubes with tissue in-growth. Designed for women seeking safe, accessible, and cost-effective permanent contraception, FemBloc avoids the risks and inconvenience of surgical sterilization. Participants are being enrolled in a pivotal clinical trial (NCT05977751) for U.S. approval. Previous clinical trials (NCT04273594, NCT03433911, and NCT03067272) have demonstrated FemBloc’s safety as a permanent birth control option compared to surgical sterilization. Learn more at www.FemBloc.com.
About Femasys
Femasys, an Atlanta-based leading biomedical innovator, develops and commercializes a portfolio of patent-protected, minimally invasive women’s health solutions, all manufactured in the U.S. Our innovative therapeutic and diagnostic products have received global regulatory approvals and are being commercialized in the U.S. and select countries. FemaSeed® Intratubal Insemination, a groundbreaking infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe and Canada. FemVue®, a companion diagnostic for fallopian tube assessment via ultrasound, is U.S. FDA-cleared with approvals in Europe, Canada and Japan. FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis, is U.S. FDA-cleared with approvals in Europe and Canada. FemBloc® permanent birth control, the Company’s late-stage product candidate, is the first and only non-surgical, in-office, method offering significant benefits over the costly, inconvenient, risk-laden surgical alternative. The fourth pivotal clinical trial (NCT05977751) is now enrolling participants for U.S. approval. FemCath® and FemChec®, companion diagnostic products for FemBloc’s ultrasound-based confirmation test, are U.S. FDA-cleared and approved in Europe and Canada. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
What new patents did Femasys (FEMY) receive for FemBloc in Europe?
When do Femasys's new European patents for FemBloc expire?
What products are included in Femasys's (FEMY) current portfolio?